Should we be moving from suppression to stimulation to deal with immunoparalysis in sepsis patients?
4th Department of Internal Medicine, University of Athens, Medical School, ATTIKON University Hospital, 1 Rimini Street, 12462 Athens, Greece and Integrated Research & Treatment Center, Center for Sepsis Control & Care, Jena University Hospital, Jena, Germany. egiamarel@med.uoa.gr.
Evangelos J
EJ
Giamarellos-Bourboulis
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology; D006801:Humans; D007114:Immunization; D007075:Immunoglobulin M / Q000276:immunology; D007136:Immunoglobulins / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology; D018805:Sepsis / Q000276:immunology* / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor